Aurobindo Pharma Limited has recently informed exchanges that its subsidiary, CuraTeQ Biologics received approval for its bevacizumab biosimilar, Bevqolva, from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for intravenous administration.
In the exchange filing, the company shared, “CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma Limited, is pleased to announce that it has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version.”
Bevacizumab is used to treat various cancers, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and ovarian cancer.
Headquartered in Hyderabad, India, CuraTeQ Biologics is dedicated to improving patient outcomes by providing high-quality, cost-effective biosimilars. The company focuses on developing treatments for cancer and autoimmune diseases, with a robust pipeline of 14 biosimilars targeting immunology and oncology. CuraTeQ offers end-to-end capabilities, from bulk drug production to finished, packaged drug products.
